Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

NCT02101021 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Pancreatic Ductal Adenocarcinoma

Interventions

DRUG: Momelotinib
DRUG: Placebo to match momelotinib
DRUG: Nab-paclitaxel
DRUG: Gemcitabine

Sponsor

Sierra Oncology LLC - a GSK company